ES2922201T3 - Procedimiento de cuantificación selectiva de agregados A-beta - Google Patents

Procedimiento de cuantificación selectiva de agregados A-beta Download PDF

Info

Publication number
ES2922201T3
ES2922201T3 ES12818996T ES12818996T ES2922201T3 ES 2922201 T3 ES2922201 T3 ES 2922201T3 ES 12818996 T ES12818996 T ES 12818996T ES 12818996 T ES12818996 T ES 12818996T ES 2922201 T3 ES2922201 T3 ES 2922201T3
Authority
ES
Spain
Prior art keywords
beta
seq
aggregates
probes
labeled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12818996T
Other languages
English (en)
Spanish (es)
Inventor
Dieter Willbold
Susanne Aileen Funke
Lei Wang-Dietrich
Eva Birkmann
Oliver Bannach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Juelich GmbH
Original Assignee
Forschungszentrum Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungszentrum Juelich GmbH filed Critical Forschungszentrum Juelich GmbH
Application granted granted Critical
Publication of ES2922201T3 publication Critical patent/ES2922201T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552—Glass or silica
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
ES12818996T 2011-12-23 2012-12-21 Procedimiento de cuantificación selectiva de agregados A-beta Active ES2922201T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011057021A DE102011057021A1 (de) 2011-12-23 2011-12-23 Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten
PCT/EP2012/076552 WO2013092952A2 (de) 2011-12-23 2012-12-21 Verfahren zur selektiven quantifizierung von a-beta-aggregaten

Publications (1)

Publication Number Publication Date
ES2922201T3 true ES2922201T3 (es) 2022-09-09

Family

ID=47624003

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12818996T Active ES2922201T3 (es) 2011-12-23 2012-12-21 Procedimiento de cuantificación selectiva de agregados A-beta

Country Status (12)

Country Link
US (1) US20150024512A1 (enExample)
EP (1) EP2794655B1 (enExample)
JP (2) JP2015502551A (enExample)
CN (1) CN104080807A (enExample)
BR (1) BR112014015392A2 (enExample)
CA (1) CA2858125A1 (enExample)
DE (1) DE102011057021A1 (enExample)
DK (1) DK2794655T3 (enExample)
ES (1) ES2922201T3 (enExample)
IL (1) IL232870B (enExample)
RU (1) RU2642314C2 (enExample)
WO (1) WO2013092952A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013106713A1 (de) * 2013-06-26 2014-12-31 Forschungszentrum Jülich GmbH Verfahren zur Ermittlung von Indikatoren zur Bestimmung von Krankheiten
WO2016053621A1 (en) * 2014-09-16 2016-04-07 Sri International Affinity reagent and catalyst discovery though fiber-optic array scanning technology
DE102015003404B4 (de) * 2015-03-18 2021-10-07 Forschungszentrum Jülich GmbH Verfahren zur Herstellung eines Standards für den Nachweis von Proteinaggregaten einer Proteinfehlfaltungserkrankung sowie Standard und dessen Verwendung
WO2017138497A1 (ja) * 2016-02-08 2017-08-17 シスメックス株式会社 被検物質の検出方法および被検物質の検出用試薬キット
JP6886854B2 (ja) * 2017-04-13 2021-06-16 シスメックス株式会社 被検物質の情報取得方法
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
DE102017005543A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Extrazellulären Vesikeln in einer Probe
DE102017010842A1 (de) * 2017-11-23 2019-05-23 Forschungszentrum Jülich GmbH Verfahren zur Quantifizierung von Proteinaggregaten einer Proteinfehlfaltungserkrankung in einer Probe
US20200400687A1 (en) * 2017-12-19 2020-12-24 Chase Therapeutics Corporation Methods for developing pharmaceuticals for treating neurodegenerative conditions
CN111518206B (zh) 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
DE102020114278A1 (de) 2020-05-28 2021-12-02 Forschungszentrum Jülich GmbH Bestimmung krankheitsspezifischer Protein-Aggregate in Stuhlproben
DE102020003794A1 (de) * 2020-06-25 2021-12-30 Forschungszentrum Jülich GmbH Verfahren, Verwendung des Verfahrens sowle Kit zum Nachweis von Bioindikatoren in einer Probe
CN116879540B (zh) * 2023-07-13 2024-04-05 香港中文大学（深圳） 一种神经元蛋白聚集体特异性检测试剂盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE462454B (sv) * 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
US7258990B2 (en) * 2004-08-19 2007-08-21 Biocept, Inc. Alleviation of non-specific binding in microarray assays
SG10201706600VA (en) * 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
CN101384279B (zh) * 2006-02-24 2012-02-22 奇斯药制品公司 抗淀粉样蛋白免疫原性组合物、方法和用途
WO2008070229A2 (en) * 2006-08-28 2008-06-12 Case Western Reserve University Detection of pathogenic aggregates of protein in a sample by homologous elisa
SG185316A1 (en) * 2007-10-19 2012-11-29 Immunas Pharma Inc ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF
US20110104821A1 (en) * 2008-05-08 2011-05-05 Takahiko Tokuda ABeta-OLIGOMER MEASUREMENT METHOD
JP5720248B2 (ja) * 2008-12-24 2015-05-20 コニカミノルタ株式会社 表面プラズモンおよび蛍光共鳴エネルギー転移を利用した免疫アッセイ
US8512677B2 (en) * 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
EP2534490B1 (en) * 2010-02-09 2015-12-16 Bristol-Myers Squibb Company Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards

Also Published As

Publication number Publication date
EP2794655A2 (de) 2014-10-29
JP6625709B2 (ja) 2019-12-25
CN104080807A (zh) 2014-10-01
DK2794655T3 (da) 2022-07-18
JP2015502551A (ja) 2015-01-22
RU2014130136A (ru) 2016-02-10
EP2794655B1 (de) 2022-04-13
RU2642314C2 (ru) 2018-01-24
BR112014015392A2 (pt) 2019-09-24
IL232870A0 (en) 2014-07-31
CA2858125A1 (en) 2013-06-27
IL232870B (en) 2020-06-30
DE102011057021A1 (de) 2013-06-27
WO2013092952A2 (de) 2013-06-27
US20150024512A1 (en) 2015-01-22
WO2013092952A3 (de) 2013-08-29
JP2019015738A (ja) 2019-01-31

Similar Documents

Publication Publication Date Title
ES2922201T3 (es) Procedimiento de cuantificación selectiva de agregados A-beta
US20240192221A1 (en) Protein sequencing method and reagents
ES2935060T3 (es) Procedimiento para la determinación de los agregados de proteínas utilizando la superficie FIDA
Sillibourne et al. Assessing the localization of centrosomal proteins by PALM/STORM nanoscopy
ES2988827T3 (es) Método in vitro para la detección precoz de un trastorno neurodegenerativo o una depresión utilizando la quinurenina como un marcador
JP2015502551A5 (enExample)
US20150037826A1 (en) Standard for quantifying pathogenic aggregates from proteins produced naturally in the body
JP2021500551A (ja) 対称性ジメチルアルギニンの検出
US20230228771A1 (en) Determination of disease-specific protein aggregates in stool samples
US11045548B2 (en) Methods for inhibiting cancer cell migration with gold nanomaterials and photothermal therapy
Huhn et al. eSylites: Synthetic Probes for Visualization and Topographic Mapping of Single Excitatory Synapses
CA2656417C (en) Process for the selective determination of pathological protein deposits
CN114761809B (zh) 预测bcl2家族蛋白靶向药物的反应性的方法
US20200319208A1 (en) Method for quantifying protein aggregates of a protein misfolding disease in a sample
WO2025099460A1 (en) Calibrator
Praseetha et al. Molecular Nanobiotechnological approaches for the detection and therapy of prion related diseases.